Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients

AIDS

Volumn 21, Issue 9, 2007, Pages 1210-1213

  Delaugerre, Constance ^a   Mathez, Dominique ^b   Peytavin, Gilles ^c   Berthé, Huguette ^b   Long, Kivan ^c   Galperine, Tatiana ^b   De Truchis, Pierre ^b  

^a HÔPITAL AMBROISE PARÉ   (France)

^b RAYMOND POINCARÉ HOSPITAL   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; LAMIVUDINE; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE DEFICIENCY; MULTIDRUG RESISTANCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT DURATION; VIROLOGY; VIRUS LOAD;

CARBAMATES; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; RITONAVIR; SULFONAMIDES; TREATMENT FAILURE; VIRAL LOAD;

EID: 34248549145     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32810fd744     Document Type: Article

References (12)

1. Barreiro P, Camino N, de Mendoza C, Valer L, Nunez M, Martin-Carbonero L, et al. Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavirboosted protease inhibitors. Int J Antimicrob Agents 2002; 20:438-443.
2. Johnson VA, Brun-Vezinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, et al. Update of the drug resistance mutations in HIV-1: fall 2006. Top HIV Med 2006; 14:125-130.
3. De Meyer S, Azijn H, Surleraux D, Jochmans D, Tahri A, Pauwels R, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005; 49:2314-2321.
4. Poveda E, Blanco F, Garcia-Gasco P, Alcolea A, Briz V, Soriano V. Successful rescue therapy with darunabir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors. AIDS 2006; 20:1558-1560.
5. Katlama C, Carvalho MT, Cooper D, De Backer K, Lefebvre E, Pedro R, et al. TMC114/r outperforms investigator-selected PI(s) in 3-class-experienced patients: week 24 primary efficacy analysis of Power 1 (TMC114-C213). In: 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil, 24-27 July 2005 [Abstract WeOaLB0102].
6. Wilkin T, Haubrich R, Steinhart C, Becker S, Conant M, Vangeneugden T, et al. TMC114/r superior of care in 3-class-experienced patients: 24-wks primary analysis of the Power 2 study (C202). In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, USA, 16-19 December 2005 [Abstract H-413].
7. De Meyer S, Hill A, De Baere I, Rimsky L, Azijn H, VanBaelen B, et al. Effect of baseline susceptibility and on-treatment mutations TMC114 and control PI efficacy. In: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA, 5-8 February 2006 [Abstract 157].
8. Sekar V, Spinosa-Guzman S, Lefebvre E, Hoetelmans R. Clinical pharmacology of TMC114 - a new HIV protease inhibitor. In: XVIth International AIDS Conference. Toronto, Canada, 13-18 August 2006 [Abstract TUPE0083].
9. King NM, Prabu-Jeyabalan M, Nalivaika EA, Wigerinck P, de Bethune MP, Schiffer CA. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol 2004; 78: 12012-12021.
10. Picchio G, Staes M, Van Craenenbroeck E, Vermeiren H, Bacheler L, De Bethune MP, et al. HIV-1 susceptibility to TMC114 among routine clinical samples with different levels of protease inhibitor susceptibility using linear regression model-based fold change predictions. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA, 27-30 September 2006 [Abstract 402].
11. Lefebvre E, de Bethune MP, De Meyer S, Vangeneugden T, De Pauw M, Cefalone M, et al. Impact of use of TPV, LPV, and(f)APV at screening on TMC114/r virologic response in treatment-experienced patients in POWER 1, 2 and 3. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA, 27-30 September 2006 [Abstract H-1387].
12. Maguire M, Shortino D, Klein A, Harris W, Manohitharajah V, Tisdale M, et al. Emergence of resistance to protease inhibitor amprenavir in human patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob Agents Chemother 2002; 46:731-738.